Lead Product Candidate

Plus Therapeutics

The purpose of the ReSPECT™ Clinical Trial is to assess the safety, tolerability, and distribution of a novel radiotherapy, Rhenium NanoLiposome (RNL™), in adults with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. ReSPECT™ is supported by the National Institutes of Health / National Cancer Institute and current enrolling patients at UT Health San Antonio and UT Southwestern Medical Center in Dallas. The principal investigators are Andrew Brenner MD PhD and Toral Patel MD. Learn more at https://www.ReSPECT-Trials.com



Request Information

By requesting information, you agree to share the email you provided at the time of registration with the exhibitor for follow-up. Click on “Submit” to share your email or “Cancel” to cancel your information request.